Выбор оптимального препарата для лечения рассеянного склероза
Аннотация
Об авторе
А. Н. БойкоРоссия
Список литературы
1. Гусев Е.И., Бойко А.Н. Некоторые клинические и медико-социальные аспекты новых методов патогенетического лечения рассеянного склероза. Ж. неврологии и психиатрии, 2001, 12: 7-12.
2. Бойко А.Н. Патогенетическое лечение рассеянного склероза и других аутоиммунных заболеваний нервной системы. Аутоиммунные заболевания в неврологии. Клиническое руководство под ред. И.А. Завалишина, МА. Пирадова, А.Н. Бойко, С.С. Никитина, Н.Н. Спирина и А.В. Переседовой. М.: РООИ «Здоровье человека», 2014, 1: 285-344.
3. Kita M. FDA-approved preventative therapies for MS: first-Line agents. Neurol Clin., 2011, 29(2): 401-409.
4. Confavreux C, O'Connor P, Comi G et aL. Oral teri-fLunomide for patients with relapsing multiple sclerosis (TOWER): a randomized, doubLe-bLind, pLacebo-controLLed phase 3 triaL. The Lancet Neurology, 2014, 13(3): 247-256.
5. Comi G, Jeffery D, Kappos L et aL. PLacebo-controLLed triaL of oraL Laquinimod for muLtipLe scLerosis. N Engl J Med., 2012, 366(11): 1000-1009.
6. MartineLLi Boneschi F, Rovaris M et aL. Mitoxantrone for muLtipLe scLerosis. Cochrane Database of Systematic Reviews, 2005, Issue 4: CD002127.
7. Oh J, O'Connor PW Safety, toLerabiLity, and efficacy of oraL therapies for reLapsing-remitting muLtipLe scLerosis. CNS Drugs., 2013, 27(8): 591-609.
8. ELovaara I, Kuusisto HW. Intravenous immuno-gLobuLins are a therapeutic option in the treatment of muLtipLe scLerosis reLapse. Clin Neuropharmacol., 2011, 34(2): 84-89.
9. Jacobs LD, Cookfair DL, Rudick RA et aL. The MuLtipLe ScLerosis CoLLaborative Research Group. IntramuscuLar interferon beta-1a for disease progression in reLapsing muLtipLe scLerosis. Ann Neurol, 1996, 39(3): 285-294.
10. PRISMS (Prevention of ReLapses and DisabiLity by Interferon beta-1a SubcutaneousLy in MuLtipLe ScLerosis) Study Group. Randomised doubLe-bLind pLacebo-controLLed study of interferon beta-1a in reLapsing/remitting muLtipLe scLerosis. Lancet, 1998, 352(9139): 1498-1504.
11. Paty DW, Li DK, UBC MS/MRI Study Group and the IFNB MuLtipLe ScLerosis Study Group. Interferon beta-1b is effective in reLapsing-remitting muLtipLe scLerosis: II: MRI anaLysis resuLts of a muLticenter, randomized, doubLe-bLind, pLacebo-controLLed triaL. Neurology. 1993, 43(4): 662-667.
12. Johnson KP, Brooks BR, Cohen JA, et aL, the CopoLymer 1 MuLtipLe ScLerosis Study Group. CopoLymer 1 reduces reLapse rate and improves disabiLity in reLapsing-remitting muLtipLe scLerosis: resuLts of a phase III muLticenter, doubLe-bLind pLacebocontroLLed triaL. Neurology. 1995, 45(7): 1268-1276.
13. Comi G, FiLippi M, WoLinsky JS, European/ Canadian GLatiramer Acetate Study Group. European/Canadian muLticenter, doubLe-bLind, randomized, pLacebo-controLLed study of the effects of gLatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with reLapsing muLtipLe scLerosis. Ann Neurol. 2001, 49(3): 290-297.
14. PoLman CH, O'Connor Pw, Havrdova E, et aL. A randomized, pLacebo-controLLed triaL of nataLi-zumab for reLapsing muLtipLe scLerosis. N Engl J Med. 2006, 354(9): 899-910.
15. MiLLer DH, Soon D, Fernando KT, et aL. MRI outcomes in a pLacebo-controLLed triaL of nataLizum-ab in reLapsing MS. Neurology. 2007, 68(17): 1390-1401.
16. Kappos L, AnteL J, Comi G, et aL. OraL fingoLimod (FTY720) for reLapsing muLtipLe scLerosis. N Engl J Med. 2006, 355(11): 1124-1140.
17. Kappos L, Radue EW, O'Connor P, et aL. A pLacebo-controLLed triaL of oraL fingoLimod in reLapsing muLtipLe scLerosis. N Engl J Med. 2010, 362(5): 387-401.
18. Rommer PS, Stuve O. Management of secondary progressive muLtipLe scLerosis: prophyLactic treatment-past, present, and future aspects. Curr Treat Options Neurol. 2013, 15(3): 241-258.
19. Hartung HP, Gonsette R, Konig N et aL. Mitoxantrone in progressive muLtipLe scLerosis: a pLacebo-controLLed, doubLe-bLind, randomized muLticentre triaL. Lancet 2002, 360: 2018-2025.
20. KLawiter EC, Cross AH, Naismith RT. The present efficacy of muLtipLe scLerosis therapeutics: Is the new 66% just the oLd 33%?_Neurology. 2009, 73(12): 984-990.
21. Poser CM, Paty DW, Scheinberg L, et aL. New diagnostic criteria for muLtipLe scLerosis: guideL-Lines for research protocoLs. Ann Neurol 1983, 13: 227-231.
22. McDonaLd WI, Compston A, Edan G et aL. Recommended diagnostic criteria for muLtipLe scLerosis: guideLines from the InternationaL PaneL on the Diagnosis of MuLtipLe ScLerosis. Ann. Neurol 2001, 50 (1): 121-127.
23. PoLman CH, ReingoLd SC, Edan G et aL. Diagnostic criteria for muLtipLe scLerosis: 2005 revisions to the McDonaLd criteria. Ann. Neurol. 2005, 58: 840-846.
24. PoLman CH, ReingoLd SC, BanweLL B, et aL. Diagnostic criteria for muLtipLe scLerosis: 2010 revisions to the McDonaLd criteria. Ann Neurol. 2011, 69(2): 292-302.
25. Sormani MP, Tintore M, Rovaris M, Rovira A, VidaL X, Bruzzi P, FiLippi M, MontaLban X. WiLL Rogers phenomenon in muLtipLe scLerosis. Ann Neurol. 2008, 64(4): 428-433.
26. Sormani MP.The WiLL Rogers phenomenon: the effect of different diagnostic criteria. J Neurol Sci. 2009, 287 SuppL 1: S46-49.
27. Schwid SR, Panitch HS. FuLL resuLts of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a muLticenter, randomized, assessor-bLinded comparison of Low-dose weekLy versus high-dose, high-frequency interferon beta-1a for reLapsing muLtipLe scLerosis. Clin Ther. 2007, 29: 2031-2048.
28. Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, CLerico M, Pipieri A, Verdun E, Giordano L, DureLLi L, INCOMIN TriaL Study Group. Every-other-day interferon beta-1b versus once-weekLy interferon beta-1a for muLtipLe scLerosis (INCOMIN TriaL) II: anaLysis of MRI responses to treatment and correLation with Nab. Mult Scler. 2006, 12(1): 72-76.
29. FLechter S, Vardi J, PoLLak L, Rabey JM. Comparison of gLatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in muLtipLe scLerosis patients: an open-LabeL 2-year foLLow-up. J Neurol Sci. 2002, 197(1-2): 51-55.
30. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of reLapsing-remitting muLtipLe scLerosis. Acta Neurol Scand. 2006, 113(5): 283-287,
31. MikoL DD, Barkhof F, Chang P et aL. Comparison of subcutaneous interferon beta-1a with gLatira-mer acetate in patients with reLapsing muLtipLe scLerosis (the REGARD study): a muLticentre, randomised, paraLLeL, open-LabeL triaL. Lancet Neurol. 2008, 7: 903-914.
32. O'Connor P, FiLippi M, Arnason B, et aL. 250 microg or 500 microg interferon beta-1b versus 20 mg gLatiramer acetate in reLapsing-remitting muLtipLe scLerosis: a prospective, randomised, muLticentre study. Lancet Neurol. 2009, 8(10): 889-997.
33. Khan OA, TseLis AC, KamhoLz JA, et aL. A prospective, open-LabeL treatment triaL to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and gLatiramer acetate (Copaxone) on the reLapse rate in reLapsing-remitting muLtipLe scLerosis. Eur J Neurol. 2001, 8(2): 141-148.
34. Pucci E, GiuLiani G, SoLari A, Simi S, Minozzi S, Di Pietrantonj C, GaLea I. NataLizumab for reLapsing remitting muLtipLe scLerosis. Cochrane Database Syst Rev. 2011 Oct 5,(10):CD007621.
35. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, MontaLban X, PeLLetier J, Stites T, Wu S, HoLdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group. Comparison of fingoLimod with interferon beta-1a in reLapsing-remitting muLtipLe scLerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011, 10(6): 520-529.
36. Cohen JA, CoLes AJ, ArnoLd DL, et aL. ALemtuzumab versus interferon beta 1a as first-Line treatment for patients with reLapsing-remitting muLtipLe scLerosis: a randomised controLLed phase 3 triaL. Lancet. 2012, 380(9856): 1819-1828.
37. CoLes AJ, Twyman CL, ArnoLd DL, et aL. ALemtuzumab for patients with reLapsing muLtipLe scLerosis after disease-modifying therapy: a randomised controLLed phase 3 triaL. Lancet. 2012, 380(9856): 1829-183.
38. Fox RJ, MiLLer DH, PhiLLips JT, et aL. PLacebo-controLLed phase 3 study of oraL BG-12 or gLat-iramer in muLtipLe scLerosis. N Engl J Med 2012, 367: 1087-1097.
39. Vermersch P, CzLonkowska A, GrimaLdi LM, et aL. A muLticenter, randomized, paraLLeL-group, rater-bLinded study comparing the effectiveness and safety of terifLunomide and subcutaneous inter-feron beta-1a in patients with reLapsing muLtipLe scLerosis. Int J MS Care. 2012 (suppL): 9-10.
Рецензия
Для цитирования:
Бойко А.Н. Выбор оптимального препарата для лечения рассеянного склероза. Медицинский Совет. 2015;(5):78-79. https://doi.org/10.21518/2079-701X-2015-5-7-18
For citation:
Boyko A.N. Selecting the best treatment for multiple sclerosis. Meditsinskiy sovet = Medical Council. 2015;(5):78-79. (In Russ.) https://doi.org/10.21518/2079-701X-2015-5-7-18